Research Article
Apremilast in Patients Difficult to Treat: A Multicentric Real-Life Long-Term Experience
Table 2
Characteristics of all patients reported.
| | Patient | Previous cDMARDs | Previous biologics | PASI baseline | PASI last-follow-up | Weeks of therapy | AEs | Discontinuation for AEs | Other diseases during therapy |
| | 1 | — | — | 8 | 1 | 202 | — | — | — | | 2 | — | — | 12 | 0 | 104 | — | — | — | | 3 | CyA, acitretin (after diagnosis of NSCLC) | Infliximab, efalizumab, etanercept, adalimumab, and ustekinumab | 15 | 0 | 108 | — | — | — | | 4 | — | — | 12 | 1 | 322 | — | — | — | | 5 | Acitretin | — | | | 244 | Diarrhoea | No | — | | 6 | MTX and prednisone | Etanercept and ixekizumab | | | 224 | — | — | — | | 7 | — | Etanercept | 10.2 | 1.4 | 168 | Diarrhoea | No | — | | 8 | CyA and acitretin | — | 12 | 0 | 208 | — | No | Nontuberculous mycobacteriosis (Mycobacterium chelonae) |
|
|
AEs: adverse effects.
|
